Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has continued to improve the outcome value results of its DurAVR™ transcatheter heart valve (THV) designed to restore normal blood flow in aortic stenosis, a serious, life-threatening heart condition which occurs when there is a narrowing of the aortic valve.
The company’s updated 30-day clinical data results continue to show strong indications of efficacy, outstripping the indicative values of market-leading products on all three core parameters.
Updated patient data
AVR has released the latest data for its 30-day results for all 28 patients treated in the First-In-Human Study and 30-day results for all 15 patients treated in the US Early Feasibility Study.
The First-in-Human cohort of 28 patients experienced improved blood flow parameter measures in all three core areas.
Effective orifice area (EOA) increased to 2.13 centimetres squared, decreasing how hard the heart needs to work, while mean pressure gradient (MPG) fell to 7.9 mmHg, decreasing the work the heart needs to do.
Patient’s doppler velocity index (DVI) also rose to 0.57, an indication that the patient is experiencing improved blood flow, one of the core goals of the treatment.
The Early Feasibility Study of 18 patients experienced very similar improvements, with EOA rising to 2.2 centimetres squared compared to current market leader product values of 1.58, MPG fell to 7.5 mmHg compared to 11.94 in market leaders, and DVI rose to 0.64 compared to 0.44.
“The data builds on the positive clinical results reported to date which demonstrate this new class of biomimetic valve outperforms the market leader, returning patients to a near normal haemodynamic (blood flow) state,” the company stated.